Zika Virus Infections - Pipeline Review, H2 2019

December 2019 | 244 pages | ID: ZA08212BA36EN
Global Markets Direct

Abstracts

Zika Virus Infections - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections - Pipeline Review, H2 2019, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 15, 40, 23 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 11 and 11 molecules, respectively.

Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Zika Virus Infections - Overview
Zika Virus Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Zika Virus Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Zika Virus Infections - Companies Involved in Therapeutics Development
Activirosomes Ltd
Acuitas Therapeutics Inc
AIM ImmunoTech Inc
Aravive Inc
Bharat Biotech Ltd
Biken Co Ltd
BioCryst Pharmaceuticals Inc
BioNet- Asia Co Ltd
Biotron Ltd
BravoVax Co Ltd
CanSino Biologics Inc
Chugai Pharmaceutical Co Ltd
Cidara Therapeutics Inc
Ciloa
Clayton Biotechnologies Inc
Cocrystal Pharma Inc
Codagenix Inc
Emergent BioSolutions Inc
Emergex Vaccines Ltd
Ennaid Therapeutics LLC
Enyo Pharma SA
Etubics Corp
Excivion Ltd
Future Medicine Co Ltd
GeneOne Life Science Inc
GeoVax Labs Inc
Greffex Inc
GT Biopharma Inc
Hawaii Biotech Inc
Heat Biologics Inc
HSRx Group
Humabs BioMed SA
IDBiologics Inc
Immunomodulation Inc
Imutex Ltd
IMV Inc
Inmunova SA
Inovio Pharmaceuticals Inc
Johnson & Johnson
KM Biologics Co Ltd
Macrophage Therapeutics Inc
Medigen Inc
Microbiotix Inc
Moderna Therapeutics Inc
Mymetics Corp
NanoViricides Inc
Novalex Therapeutics Inc
Palisades Therapeutics
Pharos Biologicals LLC
Phoenix Biotechnology Inc
Plex Pharmaceuticals Inc
Precision Virologics Inc
Prokarium Ltd
ProtInhi BV
Quratis Inc
Replikins Ltd
Riboscience LLC
Sanofi
Sementis Ltd
Spotlight Innovation Inc
Stabilitech Biopharma Ltd
Starpharma Holdings Ltd
Takeda Pharmaceutical Co Ltd
TechnoVax Inc
Themis Bioscience GmbH
Theravectys SA
Tiba Biotech LLC
Tychan Pte Ltd
Valneva SE
VBI Vaccines Inc
VenatoRx Pharmaceuticals Inc
Virocovax
Xenothera SAS
Zika Virus Infections - Drug Profiles
Zika Virus Infections - Dormant Projects
Zika Virus Infections - Discontinued Products
Zika Virus Infections - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Zika Virus Infections, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Zika Virus Infections - Pipeline by Activirosomes Ltd, H2 2019
Zika Virus Infections - Pipeline by Acuitas Therapeutics Inc, H2 2019
Zika Virus Infections - Pipeline by AIM ImmunoTech Inc, H2 2019
Zika Virus Infections - Pipeline by Aravive Inc, H2 2019
Zika Virus Infections - Pipeline by Bharat Biotech Ltd, H2 2019
Zika Virus Infections - Pipeline by Biken Co Ltd, H2 2019
Zika Virus Infections - Dormant Projects, H2 2019
Zika Virus Infections - Dormant Projects, H2 2019 (Contd..1), H2 2019
Zika Virus Infections - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Zika Virus Infections, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019